Under this designation, Boehringer Ingelheim will conduct a pivotal trial program in a patient group where prior treatment with reversible EGFR inhibitors has failed.
Andreas Barner, member of the board of managing directors of Boehringer Ingelheim and responsible for research, development and medicine, said: “We are confident that the pharmacologic evidence of activity in this indication and data from the clinical development program will support the use of BIBW 2992 for patients who have hardly any treatment option left.”